Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report.

Published online

Journal Article

Hemangiopericytoma (HPC) is a rare sarcomatous tumor arising from pericytes, a support cell found in blood vessels. These tumors can occur throughout the body, particularly in the lower extremities and retroperitoneum. In rare circumstances, HPCs can arise from the meninges. In these cases, they behave similar to meningiomas, in particular angiomatous meningiomas, but tend to be more aggressive and are likely to recur. Treatment usually focuses on surgical resection and radiotherapy with possible inclusion of chemotherapy for control of recurrent disease. We describe a case of recurrent right temporal HPC that first manifested as a paraneoplastic syndrome of oncogenic osteomalacia. Despite maximum therapy, this patient experienced multiple recurrences of the tumor, and immunohistochemical analysis revealed overexpression of platelet-derived growth factor receptor, a member of the SRC-related tyrosine kinases. After multiple recurrences, the patient's tumor has been stable with treatment with monotherapy utilizing molecularly targeted therapy to SRC-related tyrosine kinases. This is the first case report of the treatment of recurrent meningeal HPC with molecularly targeted therapy to SRC-related tyrosine kinases.

Full Text

Duke Authors

Cited Authors

  • Peters, KB; McLendon, R; Morse, MA; Vredenburgh, JJ

Published Date

  • April 8, 2010

Published In

Volume / Issue

  • 3 / 1

Start / End Page

  • 93 - 97

PubMed ID

  • 20740166

Pubmed Central ID

  • 20740166

International Standard Serial Number (ISSN)

  • 1662-6575

Digital Object Identifier (DOI)

  • 10.1159/000307468

Language

  • eng

Conference Location

  • Switzerland